SCHEMBL25866684

SCHEMBL25866684

Cc1ccc(-c2ccc(C(=O)NN)c(C)n2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.67
RAB9A P51151 5/20 0.55
NPC1 O15118 3/20 0.55
CASP3 P42574 2/20 0.55
SENP8 Q96LD8 2/20 0.55
SENP7 Q9BQF6 2/20 0.55
SENP6 Q9GZR1 2/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
MAPT P10636 1/20 0.55
NFKB1 P19838 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
ALDH1A1 P00352 3/20 0.51
RXFP1 Q9HBX9 1/20 0.51
P2RX7 Q99572 1/20 0.47
CA2 P00918 6/20 0.44
CA9 Q16790 6/20 0.44
CA4 P22748 4/20 0.44
TRPV1 Q8NER1 1/20 0.44
KDM4E B2RXH2 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30242327 1.00 SMN1; SMN2 (0.67) SMN1; SMN2RAB9ANPC1CASP3SENP8
SCHEMBL25866687 0.80 SMN1; SMN2 (0.65) SMN1; SMN2RAB9ANPC1CASP3SENP8
SCHEMBL28779577 0.80 P2RX7 (0.54) SMN1; SMN2RAB9ANPC1CASP3SENP8
SCHEMBL29647658 0.80 P2RX7 (0.54) SMN1; SMN2RAB9ANPC1CASP3SENP8
SCHEMBL6161620 0.76 P2RX7 (0.56) SMN1; SMN2MAPTALDH1A1P2RX7KDM4E
SCHEMBL31220152 0.74 P2RX7 (0.45) SMN1; SMN2RAB9ANPC1MAPTALDH1A1
SCHEMBL3512015 0.73 P2RX7 (0.53) SMN1; SMN2RAB9ANPC1L3MBTL1MAPT
SCHEMBL3491462 0.72 CTSD (0.53) L3MBTL1MAPTALDH1A1P2RX7CA2
SCHEMBL30353943 0.72 SMN1; SMN2 (0.61) SMN1; SMN2RAB9ANPC1CASP3SENP8
SCHEMBL25866749 0.72 SMN1; SMN2 (0.61) SMN1; SMN2RAB9ANPC1CASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234926-A1 2-(3-(2-METHYL-6-(P-TOLYL) PYRIDINE-3-YL) UREIDO) BENZENESULFONAMIDE AND DERIVATIVES AS INHIBITOR OF CARBONIC ANHYDRASE IX FOR THE TREATMENT OF CANCER YEDITEPE UNIVERSITESI (TR) 2023-07-27 US disclosed
US-20230234926-A1 2-(3-(2-METHYL-6-(P-TOLYL) PYRIDINE-3-YL) UREIDO) BENZENESULFONAMIDE AND DERIVATIVES AS INHIBITOR OF CARBONIC ANHYDRASE IX FOR THE TREATMENT OF CANCER YEDITEPE UNIVERSITESI (TR) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234926-A1 2-(3-(2-METHYL-6-(P-TOLYL) PYRIDINE-3-YL) UREIDO) BENZENESULFONAMIDE AND DERIVATIVES AS INHIBITOR OF CARBONIC ANHYDRASE IX FOR THE TREATMENT OF CANCER CA9, CA6, CA2 SMN1; SMN2 4462/4885RAB9A 1370/4885NPC1 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.